Document is current

Any future updates will be listed below

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Crossref DOI link: https://doi.org/10.1186/s13075-016-1021-2

Published Online: 2016-06-07

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark